{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:29:11Z","timestamp":1787758151890,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"Abstract<\/jats:title>\n \n PURPOSE:<\/jats:title>\n To assess the additive potency of low-dose atropine combined with optical measures designed to decrease myopia progression.<\/jats:p>\n <\/jats:sec>\n \n MATERIALS AND METHODS:<\/jats:title>\n This retrospective study included 104 myopic children aged 5\u201312 over 4 years, divided into five groups: daily instillation of 0.01% atropine and distance single-vision spectacles (A), 0.01% atropine and progressive addition lenses (A + PAL), 0.01% atropine and soft contact lens with peripheral blur (A + CL). Two control groups were included, prescribed bifocal spectacles or single vision (SV) spectacles. Cycloplegic spherical equivalence refraction was measured biannually, including 1 year after cessation of treatment.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n \n A significant decrease in myopia progression was noted during the 2\n nd<\/jats:sup>\n and 3\n rd<\/jats:sup>\n years of atropine treatment: A \u22120.55 \u00b1 0.55D, \u22120.15 \u00b1 0.15, \u22120.12 \u00b1 0.12D were 1\n st<\/jats:sup>\n , 2\n nd<\/jats:sup>\n , 3\n rd<\/jats:sup>\n years, respectively, A + PAL \u22120.47 \u00b1 0.37D, \u22120.10 \u00b1 0.25D, and \u22120.11 \u00b1 0.25D were 1\n st<\/jats:sup>\n , 2\n nd<\/jats:sup>\n , 3\n rd<\/jats:sup>\n years, respectively, A + CL \u22120.36 \u00b1 0.43D, \u22120.13 \u00b1 0.29D, and \u22120.10 \u00b1 0.27D were 1\n st<\/jats:sup>\n , 2\n nd<\/jats:sup>\n , 3\n rd<\/jats:sup>\n years, respectively. Myopia progression over 3 years, respectively, was \u22120.82 \u00b1 0.50D, \u22120.70 \u00b1 0.69D, \u22120.59 \u00b1 0.66D in the bifocal group and \u22121.20 \u00b1 1.28D, \u22120.72 \u00b1 0.62D, \u22120.65 \u00b1 0.47D in the SV group. One year after cessation of atropine treatment, myopia progression was \u2212 0.32 \u00b1 0.31D in A, \u22120.23 \u00b1 0.28D in A + PAL, and \u22120.18 \u00b1 0.35D in A + CL.\n <\/jats:p>\n <\/jats:sec>\n \n CONCLUSION:<\/jats:title>\n \n Atropine 0.01% presented as effective at decelerating myopia progression, more prominent in the 2\n nd<\/jats:sup>\n and 3\n rd<\/jats:sup>\n years of treatment. Combining atropine 0.01% with optical modalities exhibited a trend for added efficacy over monotherapy. A + CL exhibited the least rebound effect 1 year after cessation of treatment.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/tjo.tjo_31_22","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T06:31:41Z","timestamp":1659335501000},"page":"231-237","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Myopia control utilizing low-dose atropine as an isolated therapy or in combination with other optical measures: A retrospective cohort study"],"prefix":"10.4103","volume":"13","author":[{"given":"Nir","family":"Erdinest","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel"},{"name":"The Myopia Center, Rishon LeZion, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"London","sequence":"additional","affiliation":[{"name":"Private Practice, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Lavy","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadav","family":"Levinger","sequence":"additional","affiliation":[{"name":"Enaim Refractive Surgery Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Pras","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Assaf Harofeh Medical Center, Zerifin, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Morad","sequence":"additional","affiliation":[{"name":"The Myopia Center, Rishon LeZion, Israel"},{"name":"Department of Ophthalmology, Assaf Harofeh Medical Center, Zerifin, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"R2-20240830","first-page":"9","article-title":"Myopia:A growing epidemic","volume":"32","author":"Flanagan","year":"2019","journal-title":"Community Eye Health"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-981-13-8491-2_9","article-title":"Understanding pathologic myopia","author":"Ohno-Matsui","year":"2020","journal-title":"Updates on Myopia"},{"key":"R4-20240830","first-page":"CD004916","article-title":"Interventions to slow progression of myopia in children","volume":"1","author":"Walline","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/978-981-13-8491-2_14","article-title":"Optical interventions for myopia control","author":"Tang","year":"2020","journal-title":"Updates on Myopia"},{"key":"R6-20240830","first-page":"602","article-title":"Epidemiology of myopia and prevention of myopia progression in children in East Asia:A review","volume":"24","author":"Mak","year":"2018","journal-title":"Hong Kong Med J"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/bs.pmbts.2015.05.005","article-title":"Scleral mechanisms underlying ocular growth and myopia","volume":"134","author":"Metlapally","year":"2015","journal-title":"Prog Mol Biol Transl Sci"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/17.5.3","article-title":"Blur perception throughout the visual field in myopia and emmetropia","volume":"17","author":"Maiello","year":"2017","journal-title":"J Vis"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","article-title":"Biological mechanisms of atropine control of myopia","volume":"46","author":"Upadhyay","year":"2020","journal-title":"Eye Contact Lens"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2:Myopia control with atropine 0.01% eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","article-title":"Atropine for the treatment of childhood myopia:Changes after stopping atropine 0.01%, 0.1% and 0.5%","volume":"157","author":"Chia","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/OPX.0000000000001044","article-title":"Accommodation and phoria in children wearing multifocal contact lenses","volume":"94","author":"Gong","year":"2017","journal-title":"Optom Vis Sci"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study:A randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/OPX.0000000000001378","article-title":"Bifocal &atropine in myopia study:Baseline data and methods","volume":"96","author":"Huang","year":"2019","journal-title":"Optom Vis Sci"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/archophthalmol.2009.332","article-title":"Randomized trial of effect of bifocal and prismatic bifocal spectacles on myopic progression:Two-year results","volume":"128","author":"Cheng","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamaophthalmol.2013.7623","article-title":"Effect of bifocal and prismatic bifocal spectacles on myopia progression in children:Three-year results of a randomized clinical trial","volume":"132","author":"Cheng","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/OPX.0000000000001106","article-title":"Arandomized trial of soft multifocal contact lenses for myopia control:Baseline data and methods","volume":"94","author":"Walline","year":"2017","journal-title":"Optom Vis Sci"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clae.2020.03.018","article-title":"Overnight orthokeratology","volume":"43","author":"Bullimore","year":"2020","journal-title":"Cont Lens Anterior Eye"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/02713683.2019.1568501","article-title":"Combined atropine with orthokeratology for myopia control:Study design and preliminary results","volume":"44","author":"Tan","year":"2019","journal-title":"Curr Eye Res"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.clae.2018.10.026","article-title":"Adjunctive effect of orthokeratology and low dose atropine on axial elongation in fast-progressing myopic children \u2013A preliminary retrospective study","volume":"42","author":"Chen","year":"2019","journal-title":"Cont Lens Anterior Eye"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ophtha.2020.07.017","article-title":"Evolution of the prevalence of myopia among Taiwanese schoolchildren:A review of survey data from 1983 through 2017","volume":"128","author":"Tsai","year":"2021","journal-title":"Ophthalmology"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1167\/iovs.11-7769","article-title":"A randomized trial using progressive addition lenses to evaluate theories of myopia progression in children with a high lag of accommodation","volume":"53","author":"Berntsen","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"e0241759","DOI":"10.1371\/journal.pone.0241759","article-title":"Myopia progression varies with age and severity of myopia","volume":"15","author":"Verkicharla","year":"2020","journal-title":"PLoS One"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"8913582","DOI":"10.1155\/2019\/8913582","article-title":"The association between macular thickness and axial length in myopic eyes","volume":"2019","author":"Chung","year":"2019","journal-title":"Biomed Res Int"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bjophthalmol-2019-314619","article-title":"Longitudinal changes in axial length in high myopia:A 4-year prospective study","volume":"104","author":"Lee","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clae.2019.11.005","article-title":"Estimation of ocular axial length from conventional optometric measures","volume":"43","author":"Morgan","year":"2020","journal-title":"Cont Lens Anterior Eye"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/ICL.0000000000000505","article-title":"Axial elongation in myopic children and its association with myopia progression in the Correction of Myopia Evaluation Trial (COMET)","volume":"44","author":"Hou","year":"2018","journal-title":"Eye Cont Lens"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.tjo_31_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:07:14Z","timestamp":1787756834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.tjo_31_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo_31_22","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"assertion":[{"value":"2022-04-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}